For: | Zhang XF, Liu PY, Zhang SJ, Zhao KL, Zhao WX. Principle and progress of radical treatment for locally advanced esophageal squamous cell carcinoma. World J Clin Cases 2022; 10(35): 12804-12811 [PMID: 36569017 DOI: 10.12998/wjcc.v10.i35.12804] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v10/i35/12804.htm |
Number | Citing Articles |
1 |
Yong Chen, Shuangmei Zhu, Xiang Lan, Tianzhen Hu, Lele Ma, Hong Ye, Baoqiang Wang, Xiao He, Hanying Wang, Pranshu Sahgal. The Neoadjuvant Administration of PD‐1 Inhibitor plus Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous‐Cell Carcinoma. Journal of Clinical Pharmacy and Therapeutics 2024; 2024(1) doi: 10.1155/2024/5542947
|
2 |
Yusheng Pan. Clinical effectiveness and safety of Camrelizumab immunotherapy in treating advanced esophageal carcinoma. American Journal of Translational Research 2024; 16(10): 5880 doi: 10.62347/KMCL5401
|
3 |
Xiuli Xia, Shushan Zhao, Wenting Chen, Chao Xu, Dongqiang Zhao. CCT6A promotes esophageal squamous cell carcinoma cell proliferation, invasion and epithelial-mesenchymal transition by activating TGF-β/Smad/c-Myc pathway. Irish Journal of Medical Science (1971 -) 2023; 192(6): 2653 doi: 10.1007/s11845-023-03357-y
|
4 |
Shuang He, Liu E, Fei Chen, Zhidong Li. SCCGs_Prediction: a machine learning tool for prediction of sulfur-containing compound associated genes. Tropical Plants 2023; 2(1): 0 doi: 10.48130/TP-2023-0018
|